secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-141488
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies announces NEJM publication of Phase 3 EPITOPE trial for Viaskin Peanut in toddlers
--------------------------------------------------------------------------------

- NEJM published Phase 3 EPITOPE data showing Viaskin Peanut statistically superior to placebo in desensitizing toddlers (1-3 years) to peanut.
- Treatment responder rates: 67.0% for Viaskin Peanut vs 33.5% for placebo after 12 months.
- No FDA-approved treatment options exist for peanut-allergic children under 4 years; DBV is advancing regulatory efforts for this age group.
- Viaskin Peanut was well-tolerated with low rates of treatment-related anaphylaxis and epinephrine use; local application site reactions decreased over time.
- Editorial in NEJM called the data 'very good news' for toddlers with peanut allergy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523141488/0001193125-23-141488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523141488/d237467d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-141488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer